Cargando…

A Real-World Study of Achievement Rate and Predictive Factors of Clinical and Deep Remission to Biologics in Patients with Severe Asthma

Background: Recent advances in biologics have provided new insights into the clinical course of asthma, including disease modification, clinical remission (CR), and deep remission (DR). However, the extent to which biologics achieve CR and DR in severe asthma patients is poorly understood. Methods:...

Descripción completa

Detalles Bibliográficos
Autores principales: Oishi, Keiji, Hamada, Kazuki, Murata, Yoriyuki, Matsuda, Kazuki, Ohata, Syuichiro, Yamaji, Yoshikazu, Asami-Noyama, Maki, Edakuni, Nobutaka, Kakugawa, Tomoyuki, Hirano, Tsunahiko, Matsunaga, Kazuto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142972/
https://www.ncbi.nlm.nih.gov/pubmed/37109237
http://dx.doi.org/10.3390/jcm12082900
_version_ 1785033740192317440
author Oishi, Keiji
Hamada, Kazuki
Murata, Yoriyuki
Matsuda, Kazuki
Ohata, Syuichiro
Yamaji, Yoshikazu
Asami-Noyama, Maki
Edakuni, Nobutaka
Kakugawa, Tomoyuki
Hirano, Tsunahiko
Matsunaga, Kazuto
author_facet Oishi, Keiji
Hamada, Kazuki
Murata, Yoriyuki
Matsuda, Kazuki
Ohata, Syuichiro
Yamaji, Yoshikazu
Asami-Noyama, Maki
Edakuni, Nobutaka
Kakugawa, Tomoyuki
Hirano, Tsunahiko
Matsunaga, Kazuto
author_sort Oishi, Keiji
collection PubMed
description Background: Recent advances in biologics have provided new insights into the clinical course of asthma, including disease modification, clinical remission (CR), and deep remission (DR). However, the extent to which biologics achieve CR and DR in severe asthma patients is poorly understood. Methods: To assess the achievement rate and predictors of CR and DR using long-term biologics, we retrospectively evaluated 54 severe asthma patients recently started on biologics. “CR” denotes the achievement of all three criteria: (1) absence of asthma symptoms, (2) no asthma exacerbations, and (3) no use of oral corticosteroids. DR denoted CR plus (4) normalized pulmonary function and (5) suppressed type 2 inflammation. Results: CR and DR achievement rates were 68.5% and 31.5%, respectively. Compared with the non-deep remission group, the DR group had higher adult-onset asthma rates (94.1% vs. 70.3%, p = 0.078), shorter asthma duration (5 vs. 19 years, p = 0.006), and higher FEV(1) (91.5% vs. 71.5%, p < 0.001). There were no significant differences in the Asthma Control Questionnaire scores, exacerbation frequency, or type 2 inflammation at baseline between groups. Asthma duration combined with FEV(1) can stratify the achievement rates of CR and DR. Conclusions: the early introduction of biologics in severe asthma patients may help achieve CR and DR.
format Online
Article
Text
id pubmed-10142972
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101429722023-04-29 A Real-World Study of Achievement Rate and Predictive Factors of Clinical and Deep Remission to Biologics in Patients with Severe Asthma Oishi, Keiji Hamada, Kazuki Murata, Yoriyuki Matsuda, Kazuki Ohata, Syuichiro Yamaji, Yoshikazu Asami-Noyama, Maki Edakuni, Nobutaka Kakugawa, Tomoyuki Hirano, Tsunahiko Matsunaga, Kazuto J Clin Med Article Background: Recent advances in biologics have provided new insights into the clinical course of asthma, including disease modification, clinical remission (CR), and deep remission (DR). However, the extent to which biologics achieve CR and DR in severe asthma patients is poorly understood. Methods: To assess the achievement rate and predictors of CR and DR using long-term biologics, we retrospectively evaluated 54 severe asthma patients recently started on biologics. “CR” denotes the achievement of all three criteria: (1) absence of asthma symptoms, (2) no asthma exacerbations, and (3) no use of oral corticosteroids. DR denoted CR plus (4) normalized pulmonary function and (5) suppressed type 2 inflammation. Results: CR and DR achievement rates were 68.5% and 31.5%, respectively. Compared with the non-deep remission group, the DR group had higher adult-onset asthma rates (94.1% vs. 70.3%, p = 0.078), shorter asthma duration (5 vs. 19 years, p = 0.006), and higher FEV(1) (91.5% vs. 71.5%, p < 0.001). There were no significant differences in the Asthma Control Questionnaire scores, exacerbation frequency, or type 2 inflammation at baseline between groups. Asthma duration combined with FEV(1) can stratify the achievement rates of CR and DR. Conclusions: the early introduction of biologics in severe asthma patients may help achieve CR and DR. MDPI 2023-04-16 /pmc/articles/PMC10142972/ /pubmed/37109237 http://dx.doi.org/10.3390/jcm12082900 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Oishi, Keiji
Hamada, Kazuki
Murata, Yoriyuki
Matsuda, Kazuki
Ohata, Syuichiro
Yamaji, Yoshikazu
Asami-Noyama, Maki
Edakuni, Nobutaka
Kakugawa, Tomoyuki
Hirano, Tsunahiko
Matsunaga, Kazuto
A Real-World Study of Achievement Rate and Predictive Factors of Clinical and Deep Remission to Biologics in Patients with Severe Asthma
title A Real-World Study of Achievement Rate and Predictive Factors of Clinical and Deep Remission to Biologics in Patients with Severe Asthma
title_full A Real-World Study of Achievement Rate and Predictive Factors of Clinical and Deep Remission to Biologics in Patients with Severe Asthma
title_fullStr A Real-World Study of Achievement Rate and Predictive Factors of Clinical and Deep Remission to Biologics in Patients with Severe Asthma
title_full_unstemmed A Real-World Study of Achievement Rate and Predictive Factors of Clinical and Deep Remission to Biologics in Patients with Severe Asthma
title_short A Real-World Study of Achievement Rate and Predictive Factors of Clinical and Deep Remission to Biologics in Patients with Severe Asthma
title_sort real-world study of achievement rate and predictive factors of clinical and deep remission to biologics in patients with severe asthma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142972/
https://www.ncbi.nlm.nih.gov/pubmed/37109237
http://dx.doi.org/10.3390/jcm12082900
work_keys_str_mv AT oishikeiji arealworldstudyofachievementrateandpredictivefactorsofclinicalanddeepremissiontobiologicsinpatientswithsevereasthma
AT hamadakazuki arealworldstudyofachievementrateandpredictivefactorsofclinicalanddeepremissiontobiologicsinpatientswithsevereasthma
AT muratayoriyuki arealworldstudyofachievementrateandpredictivefactorsofclinicalanddeepremissiontobiologicsinpatientswithsevereasthma
AT matsudakazuki arealworldstudyofachievementrateandpredictivefactorsofclinicalanddeepremissiontobiologicsinpatientswithsevereasthma
AT ohatasyuichiro arealworldstudyofachievementrateandpredictivefactorsofclinicalanddeepremissiontobiologicsinpatientswithsevereasthma
AT yamajiyoshikazu arealworldstudyofachievementrateandpredictivefactorsofclinicalanddeepremissiontobiologicsinpatientswithsevereasthma
AT asaminoyamamaki arealworldstudyofachievementrateandpredictivefactorsofclinicalanddeepremissiontobiologicsinpatientswithsevereasthma
AT edakuninobutaka arealworldstudyofachievementrateandpredictivefactorsofclinicalanddeepremissiontobiologicsinpatientswithsevereasthma
AT kakugawatomoyuki arealworldstudyofachievementrateandpredictivefactorsofclinicalanddeepremissiontobiologicsinpatientswithsevereasthma
AT hiranotsunahiko arealworldstudyofachievementrateandpredictivefactorsofclinicalanddeepremissiontobiologicsinpatientswithsevereasthma
AT matsunagakazuto arealworldstudyofachievementrateandpredictivefactorsofclinicalanddeepremissiontobiologicsinpatientswithsevereasthma
AT oishikeiji realworldstudyofachievementrateandpredictivefactorsofclinicalanddeepremissiontobiologicsinpatientswithsevereasthma
AT hamadakazuki realworldstudyofachievementrateandpredictivefactorsofclinicalanddeepremissiontobiologicsinpatientswithsevereasthma
AT muratayoriyuki realworldstudyofachievementrateandpredictivefactorsofclinicalanddeepremissiontobiologicsinpatientswithsevereasthma
AT matsudakazuki realworldstudyofachievementrateandpredictivefactorsofclinicalanddeepremissiontobiologicsinpatientswithsevereasthma
AT ohatasyuichiro realworldstudyofachievementrateandpredictivefactorsofclinicalanddeepremissiontobiologicsinpatientswithsevereasthma
AT yamajiyoshikazu realworldstudyofachievementrateandpredictivefactorsofclinicalanddeepremissiontobiologicsinpatientswithsevereasthma
AT asaminoyamamaki realworldstudyofachievementrateandpredictivefactorsofclinicalanddeepremissiontobiologicsinpatientswithsevereasthma
AT edakuninobutaka realworldstudyofachievementrateandpredictivefactorsofclinicalanddeepremissiontobiologicsinpatientswithsevereasthma
AT kakugawatomoyuki realworldstudyofachievementrateandpredictivefactorsofclinicalanddeepremissiontobiologicsinpatientswithsevereasthma
AT hiranotsunahiko realworldstudyofachievementrateandpredictivefactorsofclinicalanddeepremissiontobiologicsinpatientswithsevereasthma
AT matsunagakazuto realworldstudyofachievementrateandpredictivefactorsofclinicalanddeepremissiontobiologicsinpatientswithsevereasthma